B. Metzler seel. Sohn & Co. AG Acquires 15,471 Shares of Labcorp Holdings Inc. $LH

Key Points

• B. Metzler raised its stake in Labcorp by 426.4% in Q4, buying 15,471 shares to hold 19,099 shares worth about $4.79 million after the purchase.
• Analyst sentiment is largely positive—Labcorp has an average rating of "Moderate Buy" with an average price target of $307.20, and several firms recently raised or reaffirmed outperform/overweight ratings.
• Recent results and corporate actions: Labcorp beat Q results (EPS $4.07 vs. $3.95 est.), set FY2026 guidance of $17.55–18.25 EPS, declared a $0.72 quarterly dividend (1.1% yield), and insiders sold roughly 16,113 shares (~$4.55M) over the past 90 days.

B. Metzler seel. Sohn & Co. AG grew its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 426.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 19,099 shares of the medical research company's stock after purchasing an additional 15,471 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Labcorp were worth $4,792,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dakota Wealth Management grew its position in Labcorp by 98.6% during the 3rd quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company's stock worth $2,958,000 after acquiring an additional 5,116 shares during the last quarter. Independent Advisor Alliance grew its position in Labcorp by 166.6% during the 3rd quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company's stock worth $3,477,000 after acquiring an additional 7,568 shares during the last quarter. New York State Common Retirement Fund grew its position in Labcorp by 12.0% during the 3rd quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company's stock worth $12,859,000 after acquiring an additional 4,800 shares during the last quarter. 8 Knots Management LLC grew its position in Labcorp by 96.6% during the 3rd quarter. 8 Knots Management LLC now owns 204,859 shares of the medical research company's stock worth $58,807,000 after acquiring an additional 100,675 shares during the last quarter. Finally, Cinctive Capital Management LP bought a new stake in Labcorp during the 3rd quarter worth $3,297,000. Institutional investors own 95.94% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LH shares. Robert W. Baird boosted their price objective on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Evercore restated an "outperform" rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Finally, Piper Sandler lifted their target price on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $307.20.

Labcorp Stock Down 2.9%

Shares of LH opened at $264.73 on Friday. The company has a market capitalization of $21.76 billion, a PE ratio of 25.31, a PEG ratio of 1.86 and a beta of 1.02. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The stock's 50-day moving average price is $272.74 and its two-hundred day moving average price is $268.08. Labcorp Holdings Inc. has a 12 month low of $218.76 and a 12 month high of $293.72.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm's revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 17.67 EPS for the current year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp's payout ratio is currently 27.53%.

Insiders Place Their Bets

In other news, EVP Der Vaart Sandra D. Van sold 548 shares of the business's stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president directly owned 2,579 shares of the company's stock, valued at $734,782.89. The trade was a 17.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian J. Caveney sold 1,500 shares of the business's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the transaction, the executive vice president directly owned 30,107 shares in the company, valued at $8,619,935.17. This represents a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 16,113 shares of company stock valued at $4,547,450 over the last 90 days. 0.84% of the stock is owned by company insiders.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.